Antidepressants in migraine prophylaxis: An approximation;Antidepresivos en la profilaxis de la migraña: Una aproximación

Revista de Neurologia

Volumn 38, Issue 9, 2004, Pages 864-868

  Campo Arias, Adalberto ^a  

^a UNIVERSIDAD AUTÓNOMA DE BUCARAMANGA   (Colombia)

Author keywords

Antidepressants; Comorbidity; Depression; Migraine; Prophylaxis; Treatment

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CITALOPRAM; CLORIMIPRAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAGNESIUM; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; PROTRIPTYLINE; SEROTONIN 2 RECEPTOR; SEROTONIN AGONIST; SERTRALINE; TRAZODONE; UNCLASSIFIED DRUG; VENLAFAXINE;

ANALGESIA; CLINICAL TRIAL; COMORBIDITY; DRUG ACTIVITY; DRUG MECHANISM; EMOTION; HEADACHE; HEALTH CENTER; HUMAN; MAJOR DEPRESSION; MIGRAINE; PREVALENCE; PRIMARY HEALTH CARE; PROPHYLAXIS; REVIEW; SIDE EFFECT;

EID: 3142774378     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3809.2003494     Document Type: Review

References (60)

1. Kaniecki R. Headache assessment and management. JAMA 2003; 289: 1430-3.
2. Rueda M. Prevalencia de la migraña. Medunab 2002; 5: 23-7.
3. Henry P, Auray JP, Gaudin AF, Dartigues JF, Duru G, Lantéri-Minet M, et al. Prevalence and clinical characteristics of migraine in France. Neurology 2002; 59: 232-7.
4. Pradilla G, Vesga BE, Díaz LE, Pinto NX, Sanabria CL, Baldovino BP, et al. Estudio neuroepidemiológico en la comunidad urbana de Santander Piedecuesta. Acta Med Colomb 2002; 27: 407-20.
5. Pradilla G, Vesga BE, León-Sarmiento FE, Bautista LE, Núnez LC, Vesga E, et al. Neuroepidemiología en el oriente colombiano. Rev Neurol 2002; 34: 1035-43.
6. Linet MS, Stewart WF, Celentano DD, Ziegler D, Sprecher M. An epidemiology study of headache among adolescents and young adults. JAMA 1989; 261: 2211-6.
7. Silberstein SD. Estrogens, progestins, and headache. Neurology 1991; 41: 786-93.
8. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in United States. Relation to age, income, race, and other sociodemographic factor. JAMA 1992; 267: 64-9.
9. Lipton RB, Stewart WF, Scher AI. Epidemiology and economic impact of migraine. Curr Med Res Opin 2001; 17 (Suppl 1): S4-12.
10. Judd LL, Paulus MP, Wells KB, Rapaport MH. Socioeconomic burden of subsyndromal depressive symptoms and major depression in a sample of the general population. Am J Psychiatry 1996; 153: 1411-7.
11. Kringlen E, Torgersen S, Cramer V. A Norwegian psychiatric epidemiological study. Am J Psychiatry 2001; 158: 1091-8.
12. Weissman MM, Wolk S, Goldstein RB, Moreau D, Adams P, Greenwald S, et al. Depressed adolescents grown up. JAMA 1999; 281: 1707-13.
13. Roberts RE, Attikisson CC, Rosenblat A. Prevalence of psychopathology among children and adolescents. Am J Psychiatry 1998; 155: 715-25.
14. Roberts RE, Kaplan GA, Shema SJ, Strawbridge WJ. Prevalence and correlates of depression in aging cohort: The Alameda County Study. J Gerontol 1997; 5: 258-8.
15. Klerman GL, Weissmam MM. Increasing rates of depression. JAMA 1989; 261: 2229-35.
16. Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu HG, et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 1996; 276: 293-9.
17. Weissman MM, Bland R, Joyce PR, Newman S, Wells JE, Wittchen HV. Sex differences in rates of depression: cross-national perspectives. J Affect Disord 1993; 29: 77-84.
18. Seeman MV. Psychopathology in women and men: focus on female hormones. Am J Psychiatry 1997; 154: 1641-7.
19. Weissman MM, Olfson M. Depression in women: Implications for health care research. Science 1995; 269: 799-801.
20. Kendler KS, Thornton LM, Prescott CA. Gender differences in the rate of exposure to stressful life events and sensitivity to their depressogenic effects. Am J Psychiatry 2001; 158: 587-93.
21. Solomon S. Diagnosis of primary headache disorders. Validity of the IHS criteria in clinical practice. Neurol Clin 1997; 15: 15-26.
22. Ficek SK, Wittrock DA. Subjective stress and coping in recurrent tension-type headache. Headache 1995; 35: 455-60.
23. Fan AY, Gu RJ, Zhou A. An MMPI control study: Chinese migraineurs during frequent headache attack intervals. Headache 1995; 35: 475-8.
24. Swartz KL, Pratt LA, Armenian HK, Lee LC, Eaton WW. Mental disorders and the incidence of migraine headaches in a community sample. Arch Gen Psychiatry 2000; 57: 945-50.
25. Breslau N, Davis GC, Schultz LR, Peterson EL. Migraine and major depression: a longitudinal study. Headache 1994; 34: 387-93.
26. Merikangas KR, Angst J, Isler H. Migraine and psychopathology. Result of the Zurich Cohort study of young adults. Arch Gen Psychiatry 1990; 47: 849-53.
27. Rueda M. Migraña y depresión: revisión crítica de la comorbilidad. Medunab 2001; 4: 197-202.
28. Breslau N, Schultz LR, Stewart WF, Lipton RB, Lucia VC, Welch KMA. Headache and major depression. Is the association specific to migraine? Neurology 2000; 54: 308-13.
29. Merikangas KR. Association between psychopathology and headache syndromes. Curr Opin Neurol 1995; 8: 248-51.
30. Hudson JI, Mangweth B, Pope HG, De Col C, Hausmann A, Gutweniger S, et al. Family study of affective spectrum disorder. Arch Gen Psychiatry 2003; 60: 170-7.
31. Von Korff M, Le Resche L, Dworkin SE First onset of common pain symptoms: a prospective study of depression as a risk factor. Pain 1993; 55: 251-8.
32. Simon GE, Von Korff M. Somatization and psychiatric disorders in the NIMH Epidemiologic Catchment Area Study. Am J Psychiatry 1991; 148: 1494-500.
33. Kroenke K, Jackson JL, Chamberlin J. Depressive and anxiety disorders in patients presenting with physical complaint: clinical predictor and outcome. Am J Med 1997; 103: 339-47.
34. Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current understanding and treatment. N Engl J Med 2002; 346: 257-70.
35. Rufo-Campos M. Fisiopatología de la migraña. Rev Neurol Clin 2001; 2: 263-71.
36. Ferrari MD. Migraine. Lancet 1998; 351: 1043-51.
37. 1 receptors in migraine pathophysiology and treatment. Eur J Neurol 1995; 2: 5-21.
38. Kaube H, Katsarava Z, Przywara S, Drepper J, Ellrich J, Diener HC. Acute migraine headache. Possible sensitization of neurons in the spinal trigeminal nucleus? Neurology 2000; 58: 1234-8.
39. Loder E, Tietjen GE, Marcus DA. Evaluation and management issues in migraine. J Clin Outcomes Manage 999; 6: 58-74.
40. Goadsby PT, Olesen J. Diagnosis and treatment of migraine. Br Med J 1996; 312: 1279-83.
41. Velling DA, Dodick DW, Muir JJ. Sustained-release niacin for prevention of migraine headache. Mayo Clin Proc 2003; 78: 770-1.
42. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998; 50: 466-70.
43. Kolb-Lucas K. Strategies for treating migraine. Nursing 2003; 33: 4-6.
44. Campo A, Pareja J. Tratamiento de la migraña asociada con depresión. Cuadernos de Psiquiatría de Enlace 1999; 3: 9-10.
45. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4 ed. Washington, DC: American Psychiatric Association; 1994. p. 327.
46. Pignone MP, Gaynes BN, Rushton JL, Burchell CM, Orleans CT, Mulrow CD. Screening for depression in adults: a summary of the evidence for US preventive services task force. Ann Intern Med 2002; 136: 765-76.
47. Silberstein SD. Migraine: preventive treatment. Curr Med Res Opin 2001; 17 (Suppl 1): S87-93.
48. Gibert-Rahola J. Antidepressants: pharmacological profile and clinical consequences. Int J Psychiatry Clin Practice 2001; 5: 19-28.
49. Richelson E. Pharmacology of antidepressants. Mayo Clin Proc 2001; 76: 511-27.
50. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity. Arch Intern Med 2003; 163: 2433-45.
51. Nascimento ED. Prophylaxis of migraine: open study with venlafaxine in 42 patients. Arq Neuropsiquiatr 1998; 56: 744-6.
52. Hays P. Paroxetine prevents migraine [letter]. J Clin Psychiatry 1997; 58: 30-1
53. Saper J. Double-blind trial fluoxetine: chronic daily headache and migraine. Headache 1994; 34: 476-8.
54. Bank J. A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis. Headache 1994; 34: 476-8.
55. Snow V, Weiss K, Wall EM, Mottur-Pilson C. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann Intern Med 2002; 137: 840-9.
56. Tomkins GE, Jackson JL, O'Malley PG, Balden E, Santoro JE. Treatment of chronic headache with antidepressants: a meta-analysis. Am J Med 2001; 111: 54-63.
57. Bartleson JD. Treatment of migraine headache. Mayo Clin Proc 1999; 74: 702-8.
58. Welch KMA. Drug therapy of migraine. N Engl J Med 1993; 329: 1476-83.
59. Steiner TJ, Ahmed F, Findley LJ, MacGregor EA, Wilkinson M. S-Fluoxetine in the prophylaxis of migraine: 11 double-blind randomized placebo-controlled study. Cephalalgia 1998; 18: 283-6.
60. Cates M. selecting antidepressant therapy for patients with major depression. Am J Pharmacol Educ 2001; 65: 190-4.